Language
Targeted drug greatly slows growth of a brain cancer

News

HomeHome / News / Targeted drug greatly slows growth of a brain cancer
search
RECENT NEWS

Jan 24, 2024

San Angelo Suspects Arrested for Stealing Copper from HVAC Business

Jan 27, 2024

Made in Connecticut: Kongsberg Automotive » CBIA

May 19, 2023

Crews battling fire at Cascade Die Casting

May 22, 2023

Sheet metal manufacturer breaks ground on new facility in Seguin

Aug 01, 2023

What tool steel and coating are best for stamping lamination steel?

SEND YOUR INQUIRY
SUBMIT

Aug 21, 2023

Targeted drug greatly slows growth of a brain cancer

By Matthew Herper June 4, 2023 CHICAGO — An experimental drug dramatically

By Matthew Herper June 4, 2023

CHICAGO — An experimental drug dramatically slowed the growth of glioma, a type of brain cancer, if the tumor carried a specific type of genetic alteration, researchers said Sunday, potentially sparing patients exposure to radiation and chemotherapy.

The drug, vorasidenib, is made by Servier Pharmaceuticals, a privately held drugmaker based in France. The results were presented at the annual meeting of the American Society for Clinical Oncology and published in the New England Journal of Medicine.

advertisement

Vorasidenib decreased the growth of grade 2 glioma tumors by 61%, meaning that it slowed the time it took tumors to be classified as progressing, or grow by more than a third. Progression took 11.1 months for those who took a placebo, and increased to 27.7 months for those who took vorasidenib.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Senior Writer, Medicine, Editorial Director of Events

Matthew Herper covers medical innovation — both its promise and its perils.

ASCO23

biotechnology

cancer

STAT+

This name will appear with your comment

There was an error saving your display name. Please check and try again.